- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
FDA: Dolasetron mesylate IV no longer indicated for CINV
Intravenous dolasetron mesylate (Anzemet) should no longer be used to prevent nausea and vomiting associated with cancer chemotherapy in adult or pediatric patients due to an associated dose-dependant increase in QTc prolongation, according to a recent FDA drug safety communication.
Key Points
Intravenous (IV) dolasetron mesylate (Anzemet) should no longer be used to prevent nausea and vomiting associated with cancer chemotherapy (CINV) in adult or pediatric patients due to an associated dose-dependant increase in QTc prolongation, according to a recent FDA drug safety communication.
This FDA action is in response to a randomized, placebo- and active- (moxifloxacin 400 mg) controlled crossover study of IV dolasetron mesylate in 80 healthy adults. In this trial, dolasetron mesylate IV was found to increase the QTc interval (corrected for heart rate using Fridericia's formula) on day 4 compared to placebo (after baseline correction) by as much as 14.1 ms (maximum mean change) in patients receiving the FDA-approved 100-mg dose and 36.6 ms in those receiving a supratherapeutic dose of 300 mg IV. Furthermore, the PR and QRS intervals were also prolonged by IV dolasetron mesylate. The maximum mean prolongation in the PR versus placebo was 9.8 and 33.1 ms for 100-mg and 300-mg doses, respectively.
While the affect of dolasetron mesylate IV on QTc interval prolongation has not been directly evaluated in pediatric patients, modeling based upon pharmacokinetic data suggests similar clinically relevant changes in QTc interval (predicted interval increase of 22.5 ms for the recommended 1.8 mg/kg CINV dose).
According to FDA, dolasetron mesylate IV may still be used for the prevention and treatment of PONV because the lower doses appear less likely to affect the QTc, PR, or QRS intervals. However, the CINV indication will be removed from the IV product's label and a stronger warning regarding the drug's affect on the electrical activity of the heart and its propensity to cause abnormal heart rhythms will be added to both the IV and oral formulation prescribing information.
SOURCES
FDA. FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with Use of Anzemet (Dolasetron Mesylate) [Safety Communication]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm. Accessed December 17, 2010.
FDA. Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. October 2005. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf. Accessed December 17, 2010.
Anzemet [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2009.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
